Conflict of interest: The authors declare no conflict of interest.
Recent advances of immunohistochemistry for diagnosis of renal tumors
Article first published online: 20 AUG 2013
© 2013 The Authors. Pathology International © 2013 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd
Volume 63, Issue 8, pages 381–390, August 2013
How to Cite
Kuroda, N., Tanaka, A., Ohe, C. and Nagashima, Y. (2013), Recent advances of immunohistochemistry for diagnosis of renal tumors. Pathology International, 63: 381–390. doi: 10.1111/pin.12080
- Issue published online: 20 AUG 2013
- Article first published online: 20 AUG 2013
- Manuscript Accepted: 24 JUN 2013
- Manuscript Received: 30 MAR 2013
- renal tumors;
The recent classification of renal tumors has been proposed according to genetic characteristics as well as morphological difference. In this review, we summarize the immunohistochemical characteristics of each entity of renal tumors. Regarding translocation renal cell carcinoma (RCC), TFE3, TFEB and ALK protein expression is crucial in establishing the diagnosis of Xp11.2 RCC, renal carcinoma with t(6;11)(p21;q12), and renal carcinoma with ALK rearrangement, respectively. In dialysis-related RCC, neoplastic cells of acquired cystic disease-associated RCC are positive for alpha-methylacyl-CoA racemase (AMACR), but negative for cytokeratin (CK) 7, whereas clear cell papillary RCC shows the inverse pattern. The diffuse positivity for carbonic anhydrase 9 (CA9) is diagnostic for clear cell RCC. Co-expression of CK7 and CA9 is characteristic of multilocular cystic RCC. CK7 and AMACR are excellent markers for papillary RCC and mucinous tubular and spindle cell carcinoma. CD82 and epithelial-related antigen (MOC31) may be helpful in the distinction between chromophobe RCC and renal oncocytoma. WT1 and CD57 highlights the diagnosis of metanephric adenoma. The combined panel of PAX2 and PAX8 may be useful in the diagnosis of metastatic RCC.